bevacizumab,atezolizumab
roche
['bcsm', 'atezo', ' bev ', 'imbrave050', 'hcc']
imbrave050 adjuvant atezo bev for hepatocellular cancer (hcc) #hpbcsm. #asco23 78% 65% 12 month rfs rate. what do folks think? good enough as an endpoint or wait till os data? 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23